Published in final edited form as:

Bioorg Med Chem Lett. 2007 December 15; 17(24): 6864–6870. doi:10.1016/j.bmcl.2007.10.020.

Synthesis and Evaluation of Novel Heterocyclic MMP Inhibitors

Ryuji Hayashi, Xiaomin Jin, and Gregory R. Cook*

Center for Protease Research, Department of Chemistry and Molecular Biology, North Dakota State University, Fargo, ND 58105, USA.

Abstract

A variety of novel heterocyclic compounds were synthesized and evaluated for MMP inhibition. Broad spectrum inhibition of MMPs 1, 2, 9 and 12 was found with pyridinone-based compounds while *N*-heterocyclic triazoles and tetrazoles were largely ineffective. A highly selective tetrazole inhibitor for MMP-2 was discovered.

Extracellular proteolysis plays a key role in many biological processes. Angiogenesis, wound healing, inflammatory reactions, management of the blood brain barrier, general maintenance of joints, organ development, ovulation, fetus implantation in the uterus, embryogenesis, and many others all depend on enzymes which remodel connective tissues in the extracellular matrix. A family of enzymes known as the matrix metalloproteinases (MMPs) are, at least in part, responsible for these functions. The important role of MMPs in extracellular degradation has been clearly demonstrated in many diseases including arthritis, multiple sclerosis, osteoporosis, Alzheimer's disease, cancer growth and metastasis, and periodontal disease.¹ For example, MMPs mediate extracellular matrix and basement-membrane degradation during the early stages of tumor growth particularly the gelatinases.² Abnormal levels of MMPs are observed for patients of these diseases and thus inhibition of MMPs offers a potential for new therapeutics. There are more than 24 known MMPs. The MMP family of enzymes is structurally related with a zinc-containing catalytic site. There are metalloproteinases that utilize a zinc (II) metal for catalysis of the proteolysis, and therefore, zinc binding groups (ZBGs) are crucial for designing MMP inhibitors (MMPIs). As a consequence, there have been a great deal of effort in recent years to design and prepare inhibitors of MMPs, mostly targeted at the prime side of the active site, which contains a hydrophobic S1' pocket (figure 1a). Key to the activity of almost all MMPIs is the functional group that binds the zinc atom in the active site and the P1' substituent.^{3,4} To date, the only medically approved MMPI is a tetracycline derivatives with μM range inhibitions used in the treatment of periodontal disease. In the last few decades, hydroxamate based MMPIs has been mainly studied and fair amount of structure-activity data is available on these compound. Many small molecule MMPIs with hydroxamic acid as a ZBG have shown outstanding inhibition in preclinical tests. Moreover, MMPIs with other ZBGs such as thiols, carboxylates, mercaptoalcohols,⁵ and dithiols, have shown good inhibition *in vitro*.⁶ However, clinical tests for these compounds have been disappointing. Some of the reasons for this include low oral availability, poor *in vivo* stability, pharmacokinetic problems,⁷ and undesirable side effects associated with hydroxamates. Therefore the discovery of new MMPIs with better properties and non-toxic ZBGs is critical. Recent reports demonstrate a continued optimism that MMPI therapy might be beneficial.^{8–}

Gregory.Cook@ndsu.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹⁰ Thus, we have been focused on the development of MMPIs with non-hydroxamate ZBGs, better drug-like properties, and efficient and economical synthetic routes.¹¹ Herein, we disclose the synthesis of novel heterocyclic MMPIs and results of their biological examination.

Recently, Cohen reported the investigation of pyridinone-based ZBGs for MMP inhibition and these potentially have better drug-like properties for MMPIs.¹² Based partly on this work and work ongoing in our labs, we envisioned that a strongly basic pyridinone carbonyl oxygen might efficiently coordinate to the catalytic Zn(II) in the active site of MMPs and the ester substituent could play the role of a hydrophobic P₁'.

In order to provide proof of principle for our proposed pyridinone ester-based MMPIs, we prepared a library of pyridinones containing different P₁' substituents. One of the important challenges of drug synthesis is how economical and simple the synthesis of the target molecule is. All of our novel pyridinone-ester MMPIs were prepared in one step from commercially available **1**. The results of the biological screening of pyridinone-ester structures for MMP antagonist activity are summarized in table 1.

In general, most pyridinone-based MMPIs showed better inhibition for MMP-1 over MMP-2, MMP-9, or MMP-12. Alkyl R-groups (**3-1**, **3-2**, **3-5**) provided good inhibition (25–32 μ M) for MMP-1. In the case of aromatic R-groups, simple benzyl R-group (**3-6**) inhibits MMP-1 (30 μ M). Longer alkyl chains with aromatic R-group showed diminished inhibitions for MMP-1 (**3-7**, **3-13**, **3-14**, **3-30**). Electron rich benzyl R-groups (**3-8**, **3-11**, **3-12**) were also found to be less effective. Interestingly, placing -CF₃ in either the *p*- or *m*-position (**3-9** and **3-10**) resulted in selective inhibition of MMP-1. These benzyl R-groups with electron withdrawing substitutions showed better inhibition (28 and 24 μ M) over electron rich benzyl R-groups for MMP-1. Since **3-11** and **3-12** showed good inhibition towards MMP-1, fluorinated benzyl R-groups were tested. Fluorine substitution on the *o*-position (**3-15**) showed moderate inhibition for MMPs. Fluorine substitution on both *m*-(**3-16**) and *p*-positions (**3-17**) showed good inhibition for MMP-1 (28, 23 μ M). We also tested other fluorinated compounds and in particular, **3-21** displayed the best inhibition toward MMP-1 among all of inhibitors tested (13 μ M). Compound **3-23** also showed good inhibition towards MMP-1 (19 μ M). In addition, we tested other halogen substituted aromatic rings. Chlorinated groups performed similar to fluorinated compounds with the *o*-substituted compound (**3-24**) less effective. Chlorine substitution on both *m*-(**3-25**) and *p*-positions (**3-25**) afforded good inhibition for MMP-1 (21, 26 μ M). In contrast, the *o*-brominated benzyl group (**3-27**) showed increased inhibition over the *m*-substituted analog (**3-28**) for MMP-1 (19, 22 μ M). Larger aromatic R-groups (**3-31**, **3-32**, **3-33**) resulted in diminished inhibition for MMPs. Notably, **3-34** showed good inhibition for MMP-1 (42 μ M) and MMP-2 (33 μ M). Additionally, heteroaromatic rings were also tested (**3-36**, **3-37**, **3-38**) and they showed moderate inhibitions for MMP-1.

Since sulfides are known to be good ZBGs for MMPs,¹³ pyridylthiol based MMPIs (**4**) were synthesized and tested (Table 2). Compared to pyridinone-based MMPIs, the pyridylthiols proved to be generally worse for inhibition of MMPs. The only exception was observed in **4-25** and **4-26**, which inhibited MMP-2 over MMP-1, MMP-9, or MMP-12.

As histidine imidazoles serve as ligands for the catalytic zinc in the active site of MMPs, this heterocycle should be ideal for binding the catalytic Zn. We envisioned the readily accessible triazole to be similar. Oxazoline heterocycles are also well known as ligands for Lewis acids¹⁴ and we have previously utilized them for MMP inhibition.¹¹ We hypothesized the combination of oxazoline and triazole would be useful for chelating to Zn(II) (Figure 2). Thus, oxazolinyl triazole compounds were prepared (Scheme 1). Their synthesis started from trimethylsilyl propiolic acid (**5**). Peptide coupling with the aid of *N*-hydroxysuccinimide and DCC was followed by dehydration facilitated by methanesulfonyl chloride to form

trimethylsilanylethynyl oxazoline (**8**). Removal of the silyl protecting group with tetrabutylammonium fluoride was followed by copper-catalyzed [3+2] cycloaddition¹⁵ to afford the desired triazole (**12**). Results of the biological assay are presented in Table 3. To our disappointment, these compounds were largely ineffective for inhibition of all four MMPs tested. Only the cinnamyl derivative (**12-7**) showed any activity at all with modest inhibition of MMP-2 and slightly improved inhibition of MMP-12.

We also synthesized and tested tetrazole templates as well. Using [2+3] cycloaddition mediated by Zn(II), tetrazoles were prepared in high yields (Scheme 2). Since it has been shown that bidentate ligands have much better inhibitory potency than monodentate ligands, an additional potentially chelating heterocycle was incorporated into the design. We synthesized furanyl, thiophenyl, and pyridyl substituted tetrazoles (**15**, **18**). However, these compounds were completely ineffective. Interestingly, compound **18a**, which possesses a long flexible substituent, showed selective inhibition for MMP-2 (32 μ M).

We next investigated MMPIs with potentially larger 6-membered ring chelation as illustrated by **19a** (Scheme 3). Pyridylmethyl tetrazoles **21** were prepared from cyanomethyl pyridine (**19**) in a rapid two step sequence of [3+2] cycloaddition followed by alkylation. The biological assay results are summarized in Table 4. Unfortunately compounds **21-1** through **4** showed no inhibition of MMPs. Interestingly the unsubstituted pyridylmethyl tetrazole **20** afforded complete selectivity for MMP-2 with a good level of inhibition.

In conclusion, we have prepared and evaluated novel heterocyclic MMPIs with good levels of inhibitory activity with non-hydroxamate ZBGs. Pyridinone esters afforded broad spectrum low micro molar inhibition of MMPs 1, 2, 9 and 12. These compounds are advantageous as they are small and readily accessible in one synthetic step from commercially available materials. We have also synthesized and tested a variety of chelating bis-heterocycles possessing triazole and tetrazole functionality with some displaying highly selective MMP inhibition.

General Experimental Procedure¹⁶

Thin layer chromatography (TLC) was performed on silica gel Whatman-60F glass plates, and components were visualized by illumination with UV light or by staining with potassium permanganate solution. Chromatography was performed using silica E. Merck silica gel 60 (230–400 mesh). NMR spectra were recorded in CDCl₃ on a Varian Inova 500 MHz, 400 MHz, or Varian Mercury 300 MHz spectrometer. ¹³C NMR was recorded using broad band proton decoupling. Chemical shifts are reported in relative to TMS and coupling constants in Hz. Melting points were determined without correction. Reactions were carried out under an inert atmosphere of nitrogen or argon. Solvents were dried using a nitrogen pressurized alumina column system from Solvtek.

General Procedure of Biological Assay

The compounds were tested for inhibition on MMP-1, MMP-2, MMP-9 and MMP-12¹⁷ by using the fluorogenic MMP substrate 7-(methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu (N-3-[2,4-dinitrophenyl]-L-2,3-diamino-propionyl)-Ala-Arg-NH₂ (Biomol International, Plymouth Meeting, PA), in wellplate experiments with the catalytic domains (Biomol International, Plymouth Meeting, PA) in 384-well format. The catalytic domains of MMPs (MMP-1, final concentration 85 nM; MMP-2, final concentration 24 nM; MMP-9, final concentration 18 nM; MMP-12, final concentration, 84 nM) and various concentrations (150 μ M to 1.2 μ M using 1:2 dilutions) of the test compounds were pre-mixed and incubated at 37 °C for 30 minutes prior to start of experiment. To the mixture of MMP and the test compound, was added the substrate (final concentration 7 μ M) in HEPES buffer (50 mM, 5 mM CaCl₂, 0.05% w/w Brij -35 at pH 7.5) and incubated for 30 minutes. After incubation fluorescence

intensity measurements were taken by a Molecular Devices Gemini EM microplate reader (Sunnyvale, CA), excitation at 328 nm was used, and the time course of emission at 393 nm was monitored for 45 minutes at 50 second intervals.

General Procedure for Synthesis of Pyridinone-based MMPIs

Method 1—DBU (2.4 mmol) was added to a solution of 2-hydroxy-6-picolinic acid (2.0 mmol) and bromide (2.2 mmol) in CH₃CN (10 mL). The mixture was stirred overnight at the appropriate temperature. When the reaction was completed (monitored by TLC) the mixture was quenched by addition of water (20 mL) and extracted with CH₂Cl₂ (2 × 20 mL). The combined organic layers were dried over Na₂SO₄. Removal of the solvent and purification by flash silica gel chromatography (Hexane/EtOAc 3:7) afforded the desired pyridinones.

Method 2—Alcohol (2.0 mmol) was added to the solution of 2-hydroxy-6-picolinic acid (2.0 mmol), DCC (2.0 mmol), and DMAP (0.2 mmol) in CH₂Cl₂ (10 mL) at −40 °C. The mixture was allowed to warm to room temperature and stirred overnight. When the reaction was completed (monitored by TLC) the mixture was quenched by addition of water (20 mL) and extracted with CH₂Cl₂ (2 × 20 mL). The combined organic layers were dried over Na₂SO₄. Removal of the solvent and purification by flash silica gel chromatography (Hexane/EtOAc 3:7) afforded the desired pyridinones.

General Procedure for Synthesis of Thiopyridine-based MMPIs

A mixture of **3** (1.0 mmol) and Lawson's reagent (0.6 mmol) was stirred at room temperature in THF (5 mL) overnight. Upon completion of reaction, the mixture was quenched with water (10 mL) and extracted with CH₂Cl₂ (2 × 10 mL). The combined organic layers were dried over Na₂SO₄. Removal of the solvent and purification by flash silica gel chromatography (Hexane/EtOAc 8:2) afforded the desired thiopyridines.

General for the Synthesis of Triazoles

Alkyne (10.0 mmol) was added dropwise to the solution of organic azide (10.0 mmol) in *t*-BuOH/H₂O (3:1, 15 mL). Copper metal was added and the mixture was stirred overnight at 40 °C. Once the reaction was complete, it was quenched with water (30 mL), extracted with EtOAc (2 × 30 mL) and dried over Na₂SO₄. Removal of the solvent and purification by flash silica gel chromatography (Hexane/EtOAc 1:1) afforded the desired triazoles.

Synthesis of Compound 7

To a solution of 3-(trimethylsilyl) propynoic acid (5.0 mmol) in 25 mL of THF, *N*-hydroxysuccinimide (6.0 mmol) and DCC (6.0 mmol) were added sequentially. After 2.5 h of stirring at room temperature, hydroxylamine (5.0 mmol) was added via a syringe. Stirring was maintained for additional 10 h until completion of the reaction. The precipitation was filtered, and the filtrate was evaporated at reduced pressure. The residue was taken up in EtOAc and was washed with saturated NaCl solution. The aqueous phase was extracted with EtOAc twice, the combined organic extracts were dried over Na₂SO₄ and the solvent removed under reduced pressure. Flash silica gel chromatography afforded the product as white solid.

Synthesis of Compound 8

To a stirred solution of the ynamide **7** (3.5 mmol), triethylamine (17.3 mmol) and DMAP (0.10 mmol) in 1,2-dichloroethane (20 mL), was added methanesulfonyl chloride (5.2 mmol). The resulting mixture was heated to reflux until the disappearance of the starting amide was noted. After cooling, the solvent and the excess triethylamine were evaporated at reduced pressure. The residue was purified by flash silica gel chromatography with hexane/ethyl acetate as eluent.

Synthesis of Compound 9

To a stirred solution of **8** (2.05 mmol) in 5 ml of THF was added sequentially a solution of tetrabutylammonium fluoride in THF (0.05 mmol) and 0.05 ml distilled water were added. After 30 min, the reaction mixture was diluted with 20 mL of dichloromethane and washed with 20 mL of a saturated NaCl solution. The aqueous phase, after separation, was washed with dichloromethane. The combined organic extracts were dried over Na₂SO₄ and the residue was purified by flash silica gel chromatography.

General Procedure for Tetrazoles Synthesis

A mixture of nitrile (5.0 mmol), sodium azide (5.5 mmol), zinc bromide (5.0 mmol) and water was refluxed overnight with vigorous stirring. HCl (9.0 mL, 3*N*) and ethyl acetate (25 mL) were added and the mixture was stirred until no solid was present and the aqueous layer had a PH of 1. The organic layer was separated and the aqueous layer extracted with 2 × 25 mL of ethyl acetate. The combined organic layers were dried over Na₂SO₄, filtered and evaporated. 50 mL of 0.25*N* NaOH was added and the mixture was stirred for 30 min until the original precipitate was dissolved and a suspension of zinc hydroxide was formed. The suspension was filtered and the solid washed with 5 mL of 1*N* NaOH. To the filtrate was added 10 mL of 3*N* HCl with vigorous stirring until PH of 3. The precipitate was filtered, collected and dried in the oven.

General Procedure for Alkyl Substitution¹⁸

A solution of tetrazole (0.71 mmol) in DMSO was added dropwise into a suspension of NaH (0.71 mmol) in THF (10 mL) under nitrogen at room temperature. After 15 min alkyl bromide (1.06 mmol) was added via a syringe. After 5 h, the reaction was quenched with water and extracted by ethyl acetate twice. The organic phase was washed by water and brine and dried over Na₂SO₄. The solvent was removed under reduced pressure. The product was isolated purified by flash silica gel chromatography.

Acknowledgements

We are grateful to the National Institutes of Health (NCRR-P20-RR15566) for support of this work. The molecular graphics image in figure 1a was produced using the UCSF Chimera package from the Computer Graphics Laboratory, University of California, San Francisco (supported by NIH P41 RR-01081). We are grateful to Thane Underdahl and John R. Smith who obtained IC₅₀ values for our compounds.

References

1. (a) Overall CM, López-Otín C. Nature Reviews Cancer 2002;2:657–672. (b) Summers JB, Davidsen SK. Ann. Repts. In Med. Chem 1998;33:131–140. (c) Hagmann WK, Lark MW, Becker JW. Ann. Repts. In Med. Chem 1996;31:231–140. (d) Whittaker M, Floyd CD, Brown P, Gearing AJH. Chem. Rev 1999;99:2735–2776. [PubMed: 11749499] (e) Babine RE, Bender SL. Chem. Rev 1997;97:1359–1472. [PubMed: 11851455] (f) Johnson LL, Dyer R, Hupe DJ. Current Opinion in Chemical Biology 1998;2:266–471. (g) Nagase H. Biol. Chem 1997;378:151–180. [PubMed: 9165065] (h) B P, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Invasion-Metastasis 1994–95;14:246–258. (i) Polette M, Birembaut P. Int. J. Biochem-Cell-Biol 1998;30:1195–1202. [PubMed: 9839445] (j) Ellerbroek SM, Stack MS. Bioessay 1999;21:940–949. (k) Kleiner DE, Stetler-Stevenson WG. Cancer-Chemotherapy-And-Pharmacology 1999;43:S42–S51. [PubMed: 10357558] (l) Coussens LM, Werb Z. Chemistry & Biology 1996;3:895–904. [PubMed: 8939708] (m) Watson SA, Tierney G. Biodrugs 1998;9:325–335. [PubMed: 18020568] (n) Levy DE, Lapierre F, Liang W, Ye W, Lange CW, Li X, Grobelny D, Casabonne M, Tyrrell D, Holme K, Nadzan A, Galaray RE. J. Med. Chem 1998;41:199–223. [PubMed: 9457244] (o) Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DCC, Adams SE, Gearing AJH. J. Neuroimmunology 1997;72:155–161. [PubMed: 9042108] (p) Morphy JR, Millican TA, Porter JR. Curr. Med. Chem 1995;2:743–762. (q) Hanessian S, Bouzbouz S, Boudon A, Tucker GC, Peyroulan D. Biorg. Med. Chem. Lett 1999;9:1691–1696. (r) Uitto V-J, Overall CM,

- McCulloch C. *Periodontology* 2000 2003;31:77–104. [PubMed: 12656997] (s) Sternlicht MD, Werb Z. *Ann. Rev. Cell Dev. Biol* 2001;17:463–516. [PubMed: 11687497] (t) Sternlicht MD, Coussens LM, Vu TH, Werb Z. *Matrix Metalloproteinase Inhibitors in Cancer Therapy* 2001:1–37. (u) Sternlicht MD, Bergers G. *Emerging Therapeutic Targets* 2000;4:609–633.
2. (a) Sternlicht MD, Lochter A, Simpson CJ, Huey B, Rougier J-P, Gray JW, Pinkel D, Bissell MJ, Werb Z. *Cell* 1999;98:137–146. [PubMed: 10428026] (b) Sternlicht MD, Bissell MJ, Werb Z. *Oncogene* 2000;19:1102–1113. [PubMed: 10713697]
 3. For an excellent example of a simple sulfonamide carboxylate bound to the zinc and S1' pocket, see: Pavlovsky AG, Williams MG, Ye Q-Z, Ortwine DF, Purchase CF II, White AD, Dhanaraj V, Roth BD, Johnson LL, Hupe D, Humblet C, Blundell TL. *Protein Sci* 1999;8:1455. [PubMed: 10422833]
 4. For recent studies of other potential MMPi ZBG's with model zinc complexes, see: Puerta DT, Lewis JA, Cohen SM. *J. Am. Chem. Soc.* 2004asap.
 5. Babine RE, Bender SL. *Chem. Rev* 1997;97:1359–1472. [PubMed: 11851455]
 6. Wu Z, Walsh C. *J. Am. Chem. Soc* 1996;118:1785–1786.
 7. (a) Brown PD. *APMIS* 1999;107:174–180. [PubMed: 10190295] (b) Coussens LM, Fingleton B, Matrisian LM. *Science* 2002;295:2387–2392. [PubMed: 11923519]
 8. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JWL. *Br. J. Cancer* 2002;1864–1870. [PubMed: 12085177]
 9. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC, Lambiase L, Langleben A, Shparber M, Clark J, Kaywin P, Lutzsky J, Benedetto P, Boasberg P, Harris H, Leichman G, Casciato D, Harris J, Mani S, Van Echo D, Dutta S, Culliney B, Zaknoen S, Cohn A, Byrne P, Waterhouse D, Brookes D, Garewel H, Staddon A, Cynwyd B, Einhorn L, Winston R, Berkowitz I, Keller A, Goldsmith G, Imrie C, Johnson C, Daniel F, Scarffe H, Spittle M, Charnley R, Barr H, Lloyd D, Steward W, Neoptolemos J, Falk S, Wheeler T, Cunningham D, Guillou P, Van Belle S, Moreau J, Delgado M, Houston R, Rosewicz S, Malfetheriner P, Buchler M. *Journal of Clinical Oncology* 2001;19:3447–3455. [PubMed: 11481349]
 10. Groves MD, Puduvali VK, Hess KR, Jaecle KA, Peterson P, Young WKA, Levin VA. *J. Clinical Oncology* 2002;20:1383–1388.
 11. Cook GR, Manivannan E, Underdahl T, Lukacova V, Zhang Y, Balaz S. *Bioorg. Med. Chem. Lett* 2004;14:4935.
 12. a) Puerta DT, Lewis JA, Cohen SM. *J. Am. Chem. Soc* 2004;126:8388–8389. [PubMed: 15237990] b) Jacobsen FE, Lewis JA, Cohen SM. *J. Am. Chem. Soc* 2006;128:3156. [PubMed: 16522091]
 13. Brown S, Bernardo MM, Li Z, Kotra LP, Tanaka Y, Fridman R, Mobashery S. *J. Am. Chem. Soc* 2000;122:6799–6800.
 14. McManus HA, Guiry PJ. *Chem. Rev* 2004;104:4151–4202. [PubMed: 15352789]
 15. Kolb HC, Finn MG, Sharpless KB. *Angew. Chem. Int. Ed* 2001;40:2004–2021.
 16. All compounds demonstrated adequate spectral properties consistent with their assigned structure and purity.
 17. These four were chosen to represent the majority of the MMPs. For a discussion of the similarity of MMP binding sites, see: Lukacova V, Zhang Y, Mackov M, Baricic P, Raha S, Calvo JA, Balaz S. *J. Biol. Chem* 2004;279:14194–14200. [PubMed: 14732707]
 18. Demko Z, Sharpless KB. *J. Org. Chem* 2001;66:7945–7950. [PubMed: 11722189]

Figure 1.

a) MMP-2 catalytic domain.¹² b) Hypothetical binding of pyridinone-based MPIs

Scheme 1.

Synthesis of oxazolinyl triazoles and their hypothetical binding to MMPs (**12a**).

Scheme 2.

Synthesis of furanyl-, thiophenyl-, and pyridyl-substituted tetrazoles.

Scheme 3.
Synthesis of pyridylmethyl tetrazoles and its hypothetical binding to MMPs (**19a**).

Table 1

Inhibition of MMPs with pyridinone-based inhibitors

entry	product	R	%yield	IC ₅₀ (μM) ^a			
				MMP-1	MMP-2	MMP-9	MMP-12
1	3-1	isopropyl	64 ^b	31	67	67	67
2	3-2	cyclobutyl	76 ^b	25	66	62	51
3	3-3	CH ₂ CH(CH ₃) ₂	71	37	71	69	67
4	3-4	CH ₂ CCCH ₃	56	50	70	68	71
5	3-5	cyclohexyl	64 ^b	32	101	94	71
6	3-6	benzyl	76	30	65	69	69
7	3-7	(CH ₂) ₂ C ₆ H ₅	74 ^b	47	69	81	68
8	3-8	4-Me-benzyl	35	65	73	68	69
9	3-9	3-CF ₃ -benzyl	73	28	na	na	82
10	3-10	4-CF ₃ -benzyl	51	24	112	101	64
11	3-11	3-OMe-benzyl	60	69	70	70	69
12	3-12	4-OMe-benzyl	60	99	110	100	105
13	3-13	(CH ₂) ₂ OC ₆ H ₄	35 ^b	59	na	127	79
14	3-14	(CH ₂) ₄ OC ₆ H ₄	65 ^b	67	90	94	82
15	3-15	2-F-benzyl	41	64	71	76	68
16	3-16	3-F-benzyl	59	28	70	50	41
17	3-17	4-F-benzyl	66	23	71	63	65
18	3-18	2,6-F-benzyl	59	35	66	60	60
19	3-19	2,5-F-benzyl	19	70	70	85	100
20	3-20	3,5-F-benzyl	67	41	69	71	70
21	3-21	2,4,6-F-benzyl	13	16	39	33	31
22	3-22	2,4,5-F-benzyl	40 ^c	30	86	67	56
23	3-23	CH ₂ C ₆ F ₅	70	19	64	69	63
24	3-24	2-Cl-benzyl	38	51	69	81	68
25	3-25	3-Cl-benzyl	47	21	56	67	46
26	3-26	4-Cl-benzyl	46 ^c	26	69	68	47
27	3-27	2-Br-benzyl	47	19	57	59	44
28	3-28	3-Br-benzyl	38	22	68	31	31
29	3-29	4-Br-benzyl	40	81	107	114	105
30	3-30	Cinnamyl	71	86	90	73	70
31	3-31	1-naphthyl	36	115	109	109	111
32	3-32	2-naphthyl	42	75	125	103	97
33	3-33	piperonyl	60 ^d	128	107	114	105
34	3-34	3-Ph-benzyl	50	42	33	na	99
35	3-35	3-OPh-benzyl	78 ^d	68	na	na	118
36	3-36	2-thiophenyl	52 ^d	56	73	70	65
37	3-37	3-thiophenyl	65 ^d	39	65	67	62
38	3-38	2-furyl	62 ^d	46	111	90	76
39	3-39	(CH ₂) ₄ CH ₃	49	50	103	66	68

^a na = not active (IC₅₀ > 150 μM).

^b Method 1 under 70 °C.

^c Alkyl-Cl was used.

^d Method 2.

Table 2

Inhibition of MMPs with pyridithiol-based inhibitors

entry	product	R	%yield	IC ₅₀ (μM) ^a			
				MMP-1	MMP-2	MMP-9	MMP-12
1	4-1	isopropyl	50	121	na	132	146
2	4-2	cyclobutyl	60	135	na	137	na
3	4-3	cyclohexyl	52	102	73	91	87
4	4-4	benzyl	56	101	85	88	82
5	4-5	(CH ₂) ₂ C ₆ H ₅	47	120	119	107	117
6	4-6	(CH ₂) ₃ C ₆ H ₅	60	95	100	112	85
7	4-7	3-Me-benzyl	32	na	70	70	70
8	4-8	4-Me-benzyl	43	na	98	119	81
9	4-9	3-CF ₃ -benzyl	11	134	110	126	134
10	4-10	4-CF ₃ -benzyl	46	na	125	141	94
11	4-11	3-OMe-benzyl	30	86	90	93	78
12	4-12	4-OMe-benzyl	30	108	91	95	96
13	4-13	(CH ₂) ₄ OC ₆ H ₅	33	138	63	83	78
14	4-14	3-F-benzyl	20	119	124	107	151
15	4-15	4-F-benzyl	58	120	108	120	112
16	4-16	2,6-F-benzyl	32	92	66	101	127
17	4-17	2,5-F-benzyl	30	114	79	140	117
18	4-18	2,4,5-F-benzyl	27	124	90	105	106
19	4-19	CH ₃ C ₆ F ₆	20	78	70	100	81
20	4-20	4-Cl-benzyl	16	126	96	112	115
21	4-21	2-Br-benzyl	10	na	108	na	na
22	4-22	1-naphthyl	51	na	98	na	na
23	4-23	2-naphthyl	59	99	100	119	101
24	4-24	4-Ph-benzyl	65	119	110	150	135
25	4-25	3-Ph-benzyl	30	75	42	50	52
26	4-26	3-OPh-benzyl	45	78	46	75	71
27	4-27	4-OPh-benzyl	44	114	93	110	109
28	4-28	3-thiophenyl	35	108	77	90	93
29	4-29	(CH ₃) ₅ CH ₃	60	115	85	109	105

^a na = not active (IC₅₀ > 150 μM)

Table 3

Inhibition of MMPs with oxazolinylnl triazoles based inhibitors.

entry	product	R	%yield	IC ₅₀ (μM) ^a			
				MMP-1	MMP-2	MMP-9	MMP-12
1	12-1	cyclohexene	42	na	na	na	na
2	12-2	hexyl	34	na	na	na	na
3	12-3	heptyl	35	na	na	na	na
4	12-4	benzyl	48	na	na	na	na
5	12-5	(CH ₂) ₂ C ₆ H ₅	41	na	na	na	na
6	12-6	(CH ₂) ₃ C ₆ H ₅	33	na	na	na	na
7	12-7	cinnamyl	42	na	149	na	61

^a na = not active (IC₅₀ > 150 μM)

Table 4

Inhibition of MMPs with pyridylmethyl tetrazoles.

entry	product	R	%yield	IC ₅₀ (μM) ^a			
				MMP-1	MMP-2	MMP-9	MMP-12
1	20	H	86	na	48	na	na
2	21-1	benzyl	48	na	na	na	na
3	21-2	(CH ₂) ₂ C ₆ H ₅	35	na	na	na	na
4	21-3	(CH ₂) ₃ C ₆ H ₅	38	na	na	na	na
5	21-4	cinnamyl	12	na	na	na	na

^a na = not active (IC₅₀ > 150 μM)